BriaCell Therapeutics Announces Pricing of $30 million Public Offering

Executive Summary

• BriaCell Therapeutics announced a best‑efforts public offering of 5,366,726 units at $5.59 per unit for gross proceeds of approximately $30 million.
• Each unit includes one common share (or pre‑funded warrant) and one warrant exercisable at $6.93 per share, expiring five years from issuance; warrants are expected to begin trading on Nasdaq under “BCTXL” on Jan. 14, 2026.
• Net proceeds will be used for working capital, general corporate purposes, and advancing the Company’s business objectives.

Key Details

• Units offered: 5,366,726 (each unit = 1 common share or pre‑funded warrant + 1 warrant).
• Pricing: $5.59 per unit (inclusive of pre‑funded warrant exercise price).
• Gross proceeds: Approximately $30 million before placement agent fees and offering expenses.
• Warrant terms: Immediately exercisable; purchase one common share at $6.93 per share; expire five years from issuance.
• Listing: Warrants approved for Nasdaq Capital Market listing; expected ticker BCTXL on Jan. 14, 2026.
• Closing date: Anticipated Jan. 15, 2026, subject to customary closing conditions.
• Placement agent: ThinkEquity (sole placement agent).
• Regulatory filings: Form S‑1 (File No. 333-292388) effective Jan. 13, 2026; related registration statement filed under Rule 462(b) on the same date.
• Use of proceeds: Fund working capital, general corporate purposes, and further development of BriaCell’s immunotherapy programs.

Notable Quotes

(No direct quotes were provided in the release.)